Skip to Content
Merck
All Photos(2)

Key Documents

View All Documentation

Safety Information

860581

Sigma-Aldrich

α-Methyl-α-phenylsuccinimide

99%

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Empirical Formula (Hill Notation):
C11H11NO2
CAS Number:
1497-17-2
Molecular Weight:
189.21
EC Number:
216-091-7
MDL number:
MFCD00005496
UNSPSC Code:
12352100
PubChem Substance ID:
24888515
NACRES:
NA.22

Assay

99%

form

solid

mp

83-85 °C (lit.)

functional group

phenyl

SMILES string

CC1(CC(=O)NC1=O)c2ccccc2

InChI

1S/C11H11NO2/c1-11(7-9(13)12-10(11)14)8-5-3-2-4-6-8/h2-6H,7H2,1H3,(H,12,13,14)

InChI key

UDESUGJZUFALAM-UHFFFAOYSA-N

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

860581-BULK:
860581-250MG:
860581-1G:
860581-VAR:

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
05522EE
11320TF

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Pharmacokinetics of N-desmethylmethsuximide in pediatric patients.
M V Miles et al.
The Journal of pediatrics, 114(4 Pt 1), 647-650 (1989-04-01)
N Wad et al.
Clinical neuropharmacology, 22(4), 239-240 (1999-08-12)
Serum protein binding of desmethyl-methsuximide (DM-MSM) in serum from 23 patients on polytherapy were determined using ultrafiltration and high-performance liquid chromatography. Desmethyl-methsuximide, The active metabolite of methsuximide (MSM), was found to have a moderate protein binding ranging between 45% and
M B Tennison et al.
Pediatrics, 87(2), 186-189 (1991-02-01)
Methsuximide was added to the therapeutic regimens of 25 children with intractable epilepsy. In 15 patients the drug was well tolerated and resulted in a 50% or greater reduction in seizure frequency. No serious or irreversible adverse effects were seen.
D A Coulter et al.
British journal of pharmacology, 100(4), 800-806 (1990-08-01)
1. Succinimide derivatives can be either convulsant (tetramethylsuccinimide (TMS)), or anticonvulsant (ethosuximide (ES); alpha-methyl-alpha-phenylsuccinimide (MPS)). ES, an anticonvulsant succinimide, has previously been shown to block calcium currents of thalamic neurones, while the convulsant succinimide TMS blocks gamma-aminobutyric acid (GABA) responses
D S Cardella et al.
Clinical biochemistry, 21(6), 329-331 (1988-12-01)
A method for the determination of the anti-epileptic drug methsuximide (MSM) and its active metabolite N-desmethylmethsuximide (NDM) is presented. 5-Methyl-5-phenylhydantoin is used as the internal standard. A simple solid-phase extraction procedure utilizing disposable reversed-phase C18 columns is described. Samples are
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service